FIELD: medicine.
SUBSTANCE: invention refers to medicine, more specifically to psychiatry, and may be used for prediction of the risk of delayed dyskinesia accompanying schizophrenia treatment. Schizophrenic's blood serum is examined to determine the following biological values: pre-treatment amount and relation of reduced and oxidised glutathiones. The low amount of reduced glutathione (108 mcg/ml) and the reduced to oxidised glutathione ratio index lower than 0.49 provides predicting the high risk of delayed dyskinesia in schizophrenics with underlying neuroleptic therapy.
EFFECT: method provides the pre-treatment prediction of the risk of delayed dyskinesia that enables choosing an individual therapeutic approach.
1 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| LABORATORY DIFFERENTIAL DIAGNOSTIC TECHNIQUE FOR GUIDING POSITIVE AND NEGATIVE SEMIOLOGY IN SCHIZOPHRENIC PATIENTS | 2011 |
|
RU2482486C1 |
| METHOD FOR PREDICTION OF CLINICAL EFFECTIVENESS IN SCHIZOPHRENIC PATIENTS | 2014 |
|
RU2546021C1 |
| METHOD OF TREATING PATIENTS WITH SCHIZOPRENIA | 2009 |
|
RU2415666C1 |
| METHOD OF EFFICIENCY FORECAST FOR RESIDUAL SHIZOPHRENIA TREATMENT BY ATYPICAL NEUROLEPTIC QUETIAPINE | 2007 |
|
RU2349918C1 |
| METHOD FOR PREDICTION OF EFFICACY OF LADASTEN THERAPY OF ORGANIC ASTHENIC DISORDERS | 2011 |
|
RU2459208C1 |
| METHOD FOR PREDICTING THE EFFICIENCY OF TREATING PATIENTS WITH SCHIZOPHRENIA WITH ATYPICAL NEUROLEPTIC QUETIAPIN (SEROQUEL) | 2005 |
|
RU2289137C1 |
| METHOD FOR PREDICTING THE EFFICIENCY OF TREATING RESIDUAL SCHIZOPHRENIA WITH ATYPICAL NEUROLEPTICS | 2006 |
|
RU2319155C2 |
| METHOD OF PREDICTING RISK OF DEVELOPING HYPERPROLACTINEMIA IN WOMEN WITH SCHIZOPHRENIA TAKING ANTIPSYCHOTIC THERAPY | 2023 |
|
RU2810398C1 |
| LABORATORY DIFFERENTIAL DIAGNOSTIC TECHNIQUE FOR ENDOGENOUS PSYCHOSIS | 2013 |
|
RU2522236C1 |
| METHOD FOR PREDICTING EFFECTIVENESS OF OLANZAPINE ATYPICAL ANTIPSYCHOTIC DRUG THERAPY IN SCHIZOPHRENIA PATIENTS | 2017 |
|
RU2680529C1 |
